Sankala Group’s AbbVie ABBV Stock Holding History

Sankala Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$446K	Hold	2,105	–	–	0.36%	62
2025 Q4	$489K	Buy	+2,105	New	+$480K	0.39%	63

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sankala Group's ABBV Position: Q1 2026 in Review

Sankala Group held its AbbVie (ABBV) position steady in Q1 2026 at 2,105 shares worth $446K. The position accounts for 0.36% of the portfolio, ranked #62.

Sankala Group first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. The position peaked at $489K in Q4 2025. 4,089 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Sankala Group held 2,105 shares of AbbVie worth $446K as of Q1 2026.
Sankala Group left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.36% of Sankala Group's portfolio in Q1 2026, its #62 holding.
Sankala Group first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
Sankala Group's AbbVie position peaked at $489K in Q4 2025.
4,089 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.